What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection

被引:53
作者
Khan, Shahid [1 ]
Kessler, Thomas M. [1 ]
Apostolidis, Apostolos [1 ,3 ]
Kalsi, Vinay [1 ]
Panicker, Jalesh [1 ]
Roosen, Alexander [1 ]
Gonzales, Gwen [1 ]
Haslam, Collete [1 ]
Elneil, Sohier
Fowler, Clare J. [1 ]
Dasgupta, Prokar [1 ,2 ]
机构
[1] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London WC1N 3BG, England
[2] Guys & St Thomas Hosp Natl Hlth Serv Fdn Trust, Dept Urol, London, England
[3] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Urol 2, GR-54006 Thessaloniki, Greece
关键词
urinary bladder; overactive; botulinum toxin type A; recurrence; catheterization; quality of life; TOXIN TYPE-A; QUALITY-OF-LIFE; URINARY-INCONTINENCE; SINGLE-CENTER; DOUBLE-BLIND; ANTICHOLINERGICS; EXPERIENCE; SYMPTOMS; EFFICACY; IMPACT;
D O I
10.1016/j.juro.2008.11.110
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We documented the effects of intradetrusor injections of botulinum neurotoxin type A (Botox (R)) for refractory idiopathic detrusor overactivity so that prospective patients maybe properly informed about possible improvement in quality of life, the duration of interinjection intervals and the risk of clean intermittent self-catheterization. Materials and Methods: A total of 81 consecutive patients with refractory idiopathic detrusor overactivity treated with intradetrusor injections of 200 U botulinum neurotoxin type A at 20 sites per injection course were evaluated in this prospective, nonrandomized, open label cohort study. The primary outcome was changes in quality of life, as assessed by the short form of the Urogenital Distress Inventory and the Incontinence Impact Questionnaire before and after treatment. Secondary outcomes were the interinjection interval and the need for clean intermittent self-catheterization. Results: After intradetrusor botulinum, neurotoxin type A injections there was significant improvement in quality of life, which was sustained after repeat injections. Mean Urogenital Distress Inventory and Incontinence Impact Questionnaire scores decreased from 56 to 26 and 59 to 21 after injection 1 in 81 patients, from 52 to 30 and 51 to 24 after injection 2 in 24, from 40 to 19 and 43 to 17 after injection 3 in 13, from 44 to 17 and 61 to 15 after injection 4 in 6 and from 51 to 17 and 63 to 14 after injection 5 in 4, respectively. The median interinjection interval was 15, 12, 14 and 13 months between injections 1 and 2, 2 and 3, 3 and 4, and 4 and 5, respectively. Considering a post-void residual urine of greater than 100 ml with lower urinary tract symptoms as the indication for clean intermittent self-catheterization, the overall clean intermittent self-catheterization rate after treatment was 43%. Conclusions: Intradetrusor botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity significantly improved quality of life. This effect was sustained after repeat injection. More than 2 of 5 patients with refractory idiopathic detrusor overactivity required clean intermittent self-catheterization after botulinum neurotoxin type A injections and. all prospective patients should be informed about this.
引用
收藏
页码:1773 / 1778
页数:6
相关论文
共 20 条
  • [11] Clean Intermittent Self-Catheterization: A Burden for the Patient?
    Kessler, Thomas M.
    Ryu, Gloria
    Burkhard, Fiona C.
    [J]. NEUROUROLOGY AND URODYNAMICS, 2009, 28 (01) : 18 - 21
  • [12] Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?
    Kessler, TM
    Danuser, H
    Schumacher, M
    Studer, UE
    Burkhard, FC
    [J]. NEUROUROLOGY AND URODYNAMICS, 2005, 24 (03) : 231 - 236
  • [13] Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up
    Kuschel, Stefanie
    Werner, Matthias
    Schmid, Daniel Max
    Faust, Elke
    Schuessler, Bernhard
    [J]. INTERNATIONAL UROGYNECOLOGY JOURNAL, 2008, 19 (07) : 905 - 909
  • [14] Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity
    Reitz, Andre
    Denys, Pierre
    Fermanian, Christophe
    Schurch, Brigitte
    Comperat, Eva
    Chartier-Kastler, Emmanuel
    [J]. EUROPEAN UROLOGY, 2007, 52 (06) : 1729 - 1735
  • [15] Efficacy of botulinum. toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial
    Sahai, Arun
    Khan, Mohammad Shamim
    Dasgupta, Prokar
    [J]. JOURNAL OF UROLOGY, 2007, 177 (06) : 2231 - 2236
  • [16] The Zurich experiences including 6 year results of 200 cases treated with botulinum - A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics
    Schmid, D. M. S.
    Roy-Guggenbuehl, S. G.
    Werner, M. W.
    Perucchini, D. P.
    Sulser, T. S.
    Schurch, B.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 212 - 212
  • [17] Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics
    Schmid, DM
    Sauerman, P
    Werner, M
    Schuessler, B
    Blick, N
    Muentener, M
    Strebel, RT
    Perucchini, D
    Scheiner, D
    Schaer, G
    John, H
    Reitz, A
    Hauri, D
    Schurch, B
    [J]. JOURNAL OF UROLOGY, 2006, 176 (01) : 177 - 185
  • [18] Botulinum-a toxin for treating detrusor hyperreflexia in spinal cord injured patients:: A new alternative to anticholinergic drugs?: Preliminary results
    Schurch, B
    Stöhrer, M
    Kramer, G
    Schmid, DM
    Gaul, G
    Hauri, D
    [J]. JOURNAL OF UROLOGY, 2000, 164 (03) : 692 - 697
  • [19] Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence:: Results of a single treatment, randomized, placebo controlled 6-month study
    Schurch, B
    De Sèze, M
    Denys, P
    Chartier-Kastler, E
    Haab, F
    Everaert, K
    Plante, P
    Perrouin-Verbe, B
    Kumar, C
    Fraczek, S
    Brin, MF
    [J]. JOURNAL OF UROLOGY, 2005, 174 (01) : 196 - 200
  • [20] SHORT FORMS TO ASSESS LIFE QUALITY AND SYMPTOM DISTRESS FOR URINARY-INCONTINENCE IN WOMEN - THE INCONTINENCE IMPACT QUESTIONNAIRE AND THE UROGENITAL DISTRESS INVENTORY
    UEBERSAX, JS
    WYMAN, JF
    SHUMAKER, SA
    MCCLISH, DK
    FANTL, JA
    [J]. NEUROUROLOGY AND URODYNAMICS, 1995, 14 (02) : 131 - 139